Invest with us

Dr. Tahel Altman

Tel:  +97237684938


Our Team
  • Dr. Tahel Altman CEO
    Tahel graduated from the Stanford Biodesign Innovation Fellowship, a leadership program in needs driven medical device innovation. She has earned a BSc degree (at the age of 18, cum laude) in Life-science and a MD (cum laude) both from Tel Aviv University, and completed her.
  • Prof. Tamir Tuller CSO
    Tamir completed his graduate and post doc work at Tel-Aviv University and at the Weizmann Institute of Science as a Koshland fellow. He has formal education and training in Electrical Engineering, Computer Science, Medicine and Biology (four BSc, two MSc studies, and two PhD titles). He is the author of more than 100 peer reviewed, publications in top journals, as well as several patents in the field. Among others, his publications are related to synthetic biology, computational biology, microbiology, and virology.   His multidisciplinary research focuses on the deciphering, modeling and engineering of gene expression. A co-founder of Synvaccine, Tamirís expertise are key to Synvaccine`s technology for the computer-aided design of viral genomes for various applications. 
  • Dr. Rony Oren Benaroya VP Synthetic Biologist
    Rony completed her PhD at the Hebrew University and PostDoc at the Weizmann Institute of Science and is a published author in multiple peer-reviewed journals. Before joining SynVaccine Rony was Director of Research and Preclinical Development at Bio-Vent Ltd.,a developer of anti-influenza therapy. Rony brings extensive industrial R&D development experience in the field of virology and is conducting innovative research into synthetic virology at Synvaccine.
  • Dr. Yael Tsalenchuk Senior Synthetic Virologist
    Yael completed her PhD at Hebrew University with multiple excellence prizes, during which she conducted research into the biology of the Herpes virus. Yael is a published author in multiple peer-reviewed virology journals. At Synvaccine Yael is leading cutting edge research in synthetic virology.
  • Dr. Lev Rabinovich (PhD), Senior Molecular Biologist
  • Mr. Eli Goz Computational Synthetic Biologist
    Mr. Goz is a PhD candidate in Computational Systems and Synthetic Biology at the faculty of Engineering and a fellow of E.J. Safra center for Bioinformatics in Tel-Aviv University. His research interests include computational modeling and engineering of gene expression and  application of statistical and mathematical methods to large scale analysis of complex biological data. Mr. Goz has earned his B.Sc. and M.Sc. in Mathematics from Tel-Aviv University and received various awards/distinctions during his studies. He has 15 years of experience as algorithms researcher in the high-tech industry, IDF, and the academia, covering multidisciplinary fields such as scientific computing, mathematical modeling, machine learning, and image and signal processing.  Eli is a published author in multiple peer-reviewed journals on topics related to computational modeling and engineering of viruses and analysis of large scale viral genomic data.
  • Scientific Advisory Board
  • Emeritus Prof. Stanley Plotkin (MD)
  • Prof. Ruth Arnon
  • Prof. Nava Zisapel Chairman
    Prof. Zisapel is Founder and Chief Scientific Officer of Neurim Pharmaceuticals, Ltd. She is a full professor at Tel-Aviv University with a specialization in Neuro-biochemistry and holds the Michael Gluck Chair in Neuropharmacology and ALS Research, USA. Prof. Zisapel holds a B.Sc.
    in Chemistry, a M.Sc. in Biochemistry and a Ph.D. in Biochemistry from Tel-Aviv University. She has authored, together with her students and other scientists, over 160 original research publications in peer-reviewed journals.

  • Synthetic Virology
    Design, construction, and validation
  • Initial Proof of Concept
  • System Concept Design

  • SynVaccine is a young, innovative start-up company operating within the synthetic biology space, focusing on the design and validation of synthetic viruses for the development of vaccines. SynVaccine is currently developing several preventive viral vaccines for several major human pathogens. 
    The company owns exclusive licences for disruptive technologies that enable the computational rational design of viral genomes and physical DNA editing of viral vaccine genome libraries. These are positioned to leapfrog currently used, trial and error-based technologies for vaccine development and produce a pipeline of vaccine candidates for major unmet Human health risks.


    - The proposed platform addresses a large market of viral vaccines, including various unchartered viral diseases, potentially of major impact on public health as we know it

    For more information, please visit: